2013 Volume 77 Issue 2 Pages 359-362
Background: Transcatheter aortic valve replacement (TAVR) is a new alternative treatment with acceptable early results for patients with aortic valve stenosis considered to be inoperable. The first TAVR was performed in Japan in October 2009, and a total of 51 have been performed up to February 2012. Methods and Results: Because it is not possible to disclose details for 36 patients at the time of writing due to ongoing clinical trials, the early and mid-term results of 15 patients are presented for the Edwards SAPIEN valves. Age was 83.4±6.1 years. Mean pressure gradient and aortic valve area were 60.3±21.1mmHg and 0.64±0.19cm2, respectively. Left ventricular ejection fraction was 55.5±15.4%. The Logistic EuroSCORE, EuroSCORE II, and Society of Thoracic Surgeons score were 28.5±21.5%, 11.1±15.8%, and 10.0±7.4%, respectively. All of the procedures were successful and did not require conversion to surgery. Perioperative stroke did not occur, although pacemakers were implanted in 2 patients (13.3%). At discharge, mean pressure gradient and aortic valve area were improved to 10.8±4.4mmHg and 1.77±0.36cm2, respectively. Except for 1 patient who died of cancer 7 months after operation, all patients were alive at the time of writing (11–848 days after procedure; mean follow-up period, 184 days). Conclusions: Satisfactory early and mid-term results have been achieved with TAVR, indicating that this is a good alternative to treat aortic valve stenosis. (Circ J 2013; 77: 359–362)
